Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05287022 · ClinicalTrials.gov registry record
Use of Nasal Nitric Oxide Testing in Improving Primary Ciliary Dyskinesia Clinical Care
A clinical trial of Primary Ciliary Dyskinesia, sponsored by Arkansas Children's Hospital Research Institute.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT05287022: Recruiting study of Primary Ciliary Dyskinesia, sponsored by Arkansas Children's Hospital Research Institute.
NCT05287022 is a study of Primary Ciliary Dyskinesia that is actively recruiting participants, run by Arkansas Children's Hospital Research Institute. The registered enrollment target is 150 participants, above the 89-participant average among 7 other Primary Ciliary Dyskinesia trials with a reported enrollment target (69% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05287022, a study of Primary Ciliary Dyskinesia, is actively recruiting participants, sponsored by Arkansas Children's Hospital Research Institute.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
this study is aiming at learning more about primary ciliary dyskinesia (PCD) and tests that are used to diagnose this condition. One purpose of this study is to measure the level of nitric oxide in the nasal passages and examine how often the results correlate with other tests currently done to make the diagnosis.
Primary Outcome
Individuals with PCD have characteristically low values of nNO; values below an established cut-off of 77nL/min are strongly associated with PCD in compatible clinical settings. These values are not well established for individuals who are in 2-5 years of age. nNO measurements (in nL/min) in 2-5 years of age will be compared to the diagnosis of PCD and assessed to establish diagnostic cut-offs.
Conditions Studied
Study Locations (1)
Arkansas
- Arkansas Children's Hospital - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2021-06-14 |
| Est. Completion | 2030-06 |
What NCT05287022 shows while recruiting
NCT05287022 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 89-participant average among 7 other Primary Ciliary Dyskinesia trials with a reported enrollment target (69% higher).
The record links to 1 condition, with Primary Ciliary Dyskinesia appearing as the primary indexed condition, and to 0 interventions.
NCT05287022 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT05287022 about?
NCT05287022 is a clinical study titled "Use of Nasal Nitric Oxide Testing in Improving Primary Ciliary Dyskinesia Clinical Care". this study is aiming at learning more about primary ciliary dyskinesia (PCD) and tests that are used to diagnose this condition. One purpose of this study is to measure the level of nitric oxide in the nasal passages and examine how often the results correlate with other tests currently done to make...
What is the current status of trial NCT05287022?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2021-06-14. Estimated completion is 2030-06.
What conditions does trial NCT05287022 study?
This clinical trial studies the following conditions: Primary Ciliary Dyskinesia.
Who is sponsoring clinical trial NCT05287022?
This trial is sponsored by Arkansas Children's Hospital Research Institute, which has 97 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05287022 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Ciliary Dyskinesia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia
RECRUITING · NA
-
Utility of PCD Diagnostics to Improve Clinical Care
RECRUITING · NA
-
Utility of PCD Diagnostics to Improve Clinical Care
RECRUITING
-
A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults
ACTIVE NOT RECRUITING
-
A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials
ACTIVE NOT RECRUITING
-
Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI